SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic ...

H.C. Wainwright lowered the firm’s price target on 89bio (ETNB) to $21 from $29 and keeps a Buy rating on the shares. The company announced ...

Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...

Familial chilomicronemia syndrome (FCS) is a genetic disease that causes persistent accumulation of triglycerides in the ...

Bio Inc ( ($ETNB) ) has released its Q4 earnings. Here is a breakdown of the information 89Bio Inc presented to its investors. 89bio Inc., a ...

Handelsbanken Fonder AB raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 15.4% in the fourth quarter, according to the company in its most recent disclosure ...

Rhumbline Advisers raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 2.1% in the fourth ...

As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

Recent research has highlighted the significant role of Omega-3 fatty acids in supporting heart health, including some ...

Learn more about whether Exact Sciences Corporation or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.